Ingunn M. Stromnes

This study shows that blocking TGFβ signaling in TCR-engineered T cells and enhancing antigen processing in tumor cells improves their therapeutic effectiveness against pancreatic ductal adenocarcinoma.

The paper shows that tumor-specific CD4 T cells, when activated with MHC-II tetramers and anti-CD40, remodel the pancreatic tumor microenvironment to enhance immunotherapy.

The paper uses Sleeping Beauty mutagenesis to identify BACH2 and other genes that enhance CD8+ T cell persistence and function under chronic antigen stimulation, improving engineered T cell therapies.

This study physically optimizes T cells to enhance their ability to sample and engage with pancreatic ductal adenocarcinoma tumor cells, improving therapeutic outcomes.